AstraZeneca commits to investing $50 billion in the United States over the next five years.

Russ Mould of AJ Bell says that the more business AstraZeneca has in the US, the more likely investors are to push the British pharmaceutical company to relocate its primary listing from London to New York. The company has pledged to invest $50 billion in the US over the next five years to expand its research and manufacturing operations. Mould says that AstraZeneca outlined a $3.5 billion investment plan in the US just one week after Donald Trump won the presidential election last year, and now the company is ramping up efforts to fulfill that commitment. He states that Trump's tariff system may have influenced AstraZeneca's decision. Mould says in market commentary, "AstraZeneca already has a significant business in the US, which should help to minimize the tariff risk, and new investments should further solidify this position." The stock price rose by 0.1%.